QL2109 not checked

Qilu Pharmaceutical

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
4 active
5 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“QL2109 will be given 1800 mg subcutaneously at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.”In the company’s words, NCT06742138 on ClinicalTrials.gov
Tested for
Multiple Myeloma (2 trials), Relapsed or Refractory Multiple Myeloma, Malignant Plasma Cell Neoplasms
Main trialPhase 3
“This is a randomized, double-blind, multicenter trial,parallel control designed to evaluate treatment with pomalidomide + QL2109 + dexamethasone compared with pomalidomide + DARZALEX FASPRO® + dexamethasone in the participants with relapsed or refractory Multiple Myeloma.”In the company’s words, NCT06742138 on ClinicalTrials.gov
Copy of
Darzalex Faspro (Janssen Biotech), Darzalex (Janssen Biotech)Tested side by side with the original in NCT06371534, NCT06742138, NCT07400744

Other drugs for Multiple Myeloma

All 133 drugs for Multiple Myeloma

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting Dec 2027 To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
Phase 2Recruiting Nov 2027 Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Phase 2Not yet recruiting Jun 2028 QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms
Phase 1Not yet recruiting Sep 2026 A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects
Phase 1Unknown Apr 2025 A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow QL2109

Following is part of Solo: you see every change to QL2109 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in